These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 15853661)

  • 21. Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment.
    Talaei S; Mellatyar H; Asadi A; Akbarzadeh A; Sheervalilou R; Zarghami N
    Chem Biol Drug Des; 2019 May; 93(5):760-786. PubMed ID: 30697932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs.
    Blagosklonny MV
    Leukemia; 2002 Apr; 16(4):455-62. PubMed ID: 11960322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site.
    Hadden MK; Lubbers DJ; Blagg BS
    Curr Top Med Chem; 2006; 6(11):1173-82. PubMed ID: 16842154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chaperoning oncogenes: Hsp90 as a target of geldanamycin.
    Neckers L
    Handb Exp Pharmacol; 2006; (172):259-77. PubMed ID: 16610363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.
    Schulte TW; Neckers LM
    Cancer Chemother Pharmacol; 1998; 42(4):273-9. PubMed ID: 9744771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones.
    Ochel HJ; Eichhorn K; Gademann G
    Cell Stress Chaperones; 2001 Apr; 6(2):105-12. PubMed ID: 11599571
    [No Abstract]   [Full Text] [Related]  

  • 27. Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives.
    Maroney AC; Marugan JJ; Mezzasalma TM; Barnakov AN; Garrabrant TA; Weaner LE; Jones WJ; Barnakova LA; Koblish HK; Todd MJ; Masucci JA; Deckman IC; Galemmo RA; Johnson DL
    Biochemistry; 2006 May; 45(17):5678-85. PubMed ID: 16634649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin.
    Roe SM; Prodromou C; O'Brien R; Ladbury JE; Piper PW; Pearl LH
    J Med Chem; 1999 Jan; 42(2):260-6. PubMed ID: 9925731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer.
    Bagatell R; Khan O; Paine-Murrieta G; Taylor CW; Akinaga S; Whitesell L
    Clin Cancer Res; 2001 Jul; 7(7):2076-84. PubMed ID: 11448926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
    Donnelly A; Blagg BS
    Curr Med Chem; 2008; 15(26):2702-17. PubMed ID: 18991631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitors of the HSP90 molecular chaperone: current status.
    Sharp S; Workman P
    Adv Cancer Res; 2006; 95():323-48. PubMed ID: 16860662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins.
    Shimamura T; Lowell AM; Engelman JA; Shapiro GI
    Cancer Res; 2005 Jul; 65(14):6401-8. PubMed ID: 16024644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natural product origins of Hsp90 inhibitors.
    Uehara Y
    Curr Cancer Drug Targets; 2003 Oct; 3(5):325-30. PubMed ID: 14529384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Geldanamycin, a heat shock protein 90-binding benzoquinone ansamycin, inhibits steroid-dependent translocation of the glucocorticoid receptor from the cytoplasm to the nucleus.
    Czar MJ; Galigniana MD; Silverstein AM; Pratt WB
    Biochemistry; 1997 Jun; 36(25):7776-85. PubMed ID: 9201920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
    Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Geldanamycin analogs.
    Sausville EA
    J Chemother; 2004 Nov; 16 Suppl 4():68-9. PubMed ID: 15688614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin.
    Segnitz B; Gehring U
    J Biol Chem; 1997 Jul; 272(30):18694-701. PubMed ID: 9228040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heat shock protein 90 modulates the unfolded protein response by stabilizing IRE1alpha.
    Marcu MG; Doyle M; Bertolotti A; Ron D; Hendershot L; Neckers L
    Mol Cell Biol; 2002 Dec; 22(24):8506-13. PubMed ID: 12446770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37.
    Nony P; Gaude H; Rossel M; Fournier L; Rouault JP; Billaud M
    Oncogene; 2003 Dec; 22(57):9165-75. PubMed ID: 14668798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation.
    Wang J; Li Z; Lin Z; Zhao B; Wang Y; Peng R; Wang M; Lu C; Shi G; Shen Y
    Cancer Lett; 2015 Jun; 362(1):83-96. PubMed ID: 25813406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.